On Monday, Teva Pharmaceutical ADR earned an upgrade to its Relative Strength (RS) Rating, from 65 to 74.
When To Sell Stocks To Lock In Profits And Minimize Losses
This exclusive rating from Investor's Business Daily identifies price movement with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the last 52 weeks stacks up against all the other stocks in our database.
Decades of market research shows that the market's biggest winners tend to have an RS Rating north of 80 as they begin their largest climbs. See if Teva Pharmaceutical ADR can continue to show renewed price strength and clear that threshold.
Teva Pharmaceutical ADR is not currently showing a potential entry point. See if the stock goes on to form a promising consolidation that could launch a new move.
Top and bottom line growth moved higher in the company's most recent quarter. Earnings were up 8%, compared to -29% in the prior report. Revenue increased from -5% to 2%.
The company earns the No. 5 rank among its peers in the Medical-Generic Drugs industry group. Dr. Reddy's Labs ADR is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
